文献速递心外重症与机械循环支持

VA-ECMO不常规全身抗凝可减少不良事件

Venoarterial-Extracorporeal Membrane Oxygenation Without Routine Systemic Anticoagulation Decreases Adverse Events.
PubMed 文献 · Ann Thorac Surg · 2019-09-26

该单中心回顾性研究纳入203例VA-ECMO成人患者,35%(75例)未抗凝。

要点

  • VA-ECMO不常规全身抗凝不增加死亡、泵衰竭或血栓并发症风险。
  • 不抗凝组总体并发症更低,红细胞和血小板输注量显著减少。
  • 无其他抗凝指征的VA-ECMO患者可考虑不进行全身抗凝。

核心结论

  • VA-ECMO患者不常规全身抗凝与不增加死亡率、泵衰竭或血栓并发症相关。
  • 不抗凝组输血需求更低且HIT发生率为0%。
  • 无其他抗凝指征的VA-ECMO患者可不进行全身抗凝。

研究设计与样本

  • 单中心回顾性研究,纳入2011年5月至2018年1月203例VA-ECMO成人患者。
  • 按抗凝策略分层,35%(75例)未抗凝。
  • 主要结局为出血和血栓并发症的复合终点。

临床怎么用

  • 对无其他抗凝指征的VA-ECMO患者,可考虑不进行常规全身抗凝。
  • 不抗凝策略可能减少输血需求和HIT发生。

局限性

  • 回顾性单中心设计,可能存在选择偏倚。
  • 样本量有限,部分结局差异未达统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite limited evidence, systemic anticoagulation is the current standard of care for patients supported on venoarterial-extracorporeal membrane oxygenation (VA-ECMO). We hypothesized that not anticoagulating patients on VA-ECMO would decrease complications. METHODS: We retrospectively reviewed adult patients supported on VA-ECMO at our institution. Patients were stratified based on anticoagulation strategy. The primary outcome was a composite of hemorrhagic and thrombotic complications. Secondary outcomes included blood product use, incidence of heparin-induced thrombocytopenia (HIT), hospital length of stay, and in-hospital mortality. RESULTS: From May 2011 through January 2018, there were 203 eligible patients supported on VA-ECMO, 35% (75 patients) were not anticoagulated. Overall complication rates were significantly lower for the no anticoagulation group (57% versus 76%; P = .007) including a trend toward fewer hemorrhagic complications (53% versus 63%; P = .178) without increased risk of thrombosis (13% versus 21%; P = .147). The anticoagulated group required more transfusions of packed red blood cells (12.8 versus 1.09; P = .002) and platelets (3.0 versus 1.3; P = .009) and showed a higher incidence of HIT (8% versus 0%; P = .015). No difference was found in overall mortality (72% versus 62%; P = .165). CONCLUSIONS: The absence of routine systemic anticoagulation for patients supported on VA-ECMO is not associated with higher mortality, pump failure, or thrombotic complications. Patients had a lower requirement for blood product transfusions, and there was no incidence of HIT. Patients supported on VA-ECMO without other indications for anticoagulation can be treated without systemic anticoagulation during their VA-ECMO course.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Wood KL, Ayers B, Gosev I, et al. Venoarterial-Extracorporeal Membrane Oxygenation Without Routine Systemic Anticoagulation Decreases Adverse Events. Ann Thorac Surg. 2019. PMID: 31563493. doi:10.1016/j.athoracsur.2019.08.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。